SeekingAlpha · Sep 23, 2026
Gilead: HIV Growth Is Not Enough At The Current Price
Gilead Sciences is rated Sell, with a $97.46 fair value versus the $150.56 closing price, implying 35.3% downside. Click for more on the GILD stock.
NYSE · GILD
Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General
$150.93
Up+$0.64 (+0.42%)
Updated Sep 28, 2026, 4:07 PM
SID Score
7.5/10
Composite research score
Smart Money
44/100
Neutral
- Market cap
- 152.89B
- P/E ratio
- 18.89
- Dividend yield
- 2.60%
- 52-week range
- $116.88 – $157.29
- Volume
- 5.28M
- Avg. volume
- 7.34M
Price performance · GILD
GILD price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Sep 25, 2026
GILD closed at $150.93 after 19 trading sessions, up 3.14% for the selected period.
- Last close
- $150.93
- Period change
- +3.14%
- Period low
- $143.72
- Period high
- $152.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $150.05 | $151.00 | $148.02 | $150.93 | 5.28M |
| Sep 24, 2026 | $151.10 | $152.975 | $149.59 | $149.69 | 5.08M |
| Sep 23, 2026 | $153.60 | $154.1999 | $150.06 | $151.37 | 6.19M |
| Sep 22, 2026 | $150.645 | $153.2807 | $148.65 | $152.67 | 5.08M |
| Sep 21, 2026 | $150.11 | $152.095 | $148.22 | $150.56 | 5.57M |
| Sep 18, 2026 | $150.56 | $153.23 | $149.57 | $150.11 | 16.42M |
| Sep 17, 2026 | $148.775 | $151.04 | $146.8901 | $150.89 | 7.84M |
| Sep 16, 2026 | $146.58 | $149.30 | $146.12 | $147.68 | 5.19M |
| Sep 15, 2026 | $144.002 | $146.35 | $142.94 | $146.30 | 4.54M |
| Sep 14, 2026 | $144.26 | $146.75 | $143.71 | $146.41 | 4.92M |
| Sep 11, 2026 | $145.24 | $145.99 | $143.50 | $143.72 | 4.2M |
| Sep 10, 2026 | $145.07 | $145.9066 | $143.67 | $144.81 | 6.02M |
| Sep 9, 2026 | $145.46 | $147.68 | $145.00 | $145.65 | 4.58M |
| Sep 8, 2026 | $146.98 | $148.6491 | $145.45 | $146.64 | 6.08M |
| Sep 4, 2026 | $149.23 | $151.185 | $149.23 | $150.995 | 6.18M |
| Sep 3, 2026 | $150.67 | $151.48 | $148.41 | $151.22 | 4.5M |
| Sep 2, 2026 | $150.00 | $152.55 | $148.83 | $149.61 | 4.92M |
| Sep 1, 2026 | $148.52 | $149.96 | $146.915 | $149.92 | 4.87M |
| Aug 31, 2026 | $144.23 | $147.22 | $143.175 | $146.34 | 6.59M |
Latest GILD news
The latest Smart Investors Daily articles mentioning GILD.
Stock researchCompany · Overview
GILD research
Overview
Company profile and research snapshot.
Company profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $130.64
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Buy | — |
| Aug 5, 2026 | RBC Capital | Sector Perform | — |
| Aug 5, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 5, 2026 | Needham | Buy | — |
| Jul 29, 2026 | Barclays | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 22, 2026
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $152.67, moving +1.4% from the previous trading session.
Yahoo · Sep 21, 2026
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
Yahoo · Sep 21, 2026
Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers
The drugmaker expects growth in line with industry peers as it works to rebuild its pipeline beyond obesity
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
